Sunday - February 1, 2026
Johnson & Johnson Receives CHMP Positive Opinion for Akeega for the Treatment of Patients With Metastatic Hormone-Sensitive Prostate Cancer With BRCA1/2 Mutations
January 31, 2026
RARITAN, New Jersey, Jan. 31 -- Johnson and Johnson Innovative Medicine issued the following news release:

* * *

Johnson & Johnson receives CHMP positive opinion for AKEEGA(R) (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene al . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products